Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Inv. presentation
Filed Chapter 11
Monthly oper. report
|
|
BIOVEST INTERNATIONAL INC (BVTI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/07/2012 |
8-K
| Investor presentation |
| 05/31/2012 |
8-K
| Investor presentation|
Docs:
|
"Biovest Interviewed by OneMedRadio; Discusses Key Milestones Expected to Establish BiovaxID ® as the World's First Personalized Cancer Vaccine for the Treatment of Non-Hodgkin's Lymphoma TAMPA, FL and MINNEAPOLIS, MN - May 31, 2012 - Biovest International, Inc. , a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. , today announced that Brett Johnson, President and Executive Editor of OneMedPlace interviewed Biovest's President and CEO, Samuel S. Duffey, and its Senior Vice President, Product Development & Regulatory Affairs, Carlos F. Santos, Ph.D. In the webcast audio interview on OneMedRadio, Biovest discussed its global regulatory strategy for BiovaxID ® , Biovest's personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma, including plans to file ...",
"A PowerPoint presentation, portions of which are incorporated in the video presentation of the Biovest Interview by OneMedRadio referenced in attached hereto and which may be used from time to time in presentations to various third parties" |
|
| 04/19/2012 |
8-K
| Investor presentation |
| 10/06/2011 |
8-K
| Investor presentation|
Docs:
|
"Biovest Reports on Regulatory Strategy for Personalized Cancer Vaccine Targeting Non-Hodgkin's Lymphoma TAMPA, FL and MINNEAPOLIS, MN - October 6, 2011 - Biovest International, Inc. , a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. , today announced that it has started the process to conduct clinical pre-filing discussions with various regulatory agencies including Health Canada, the U.S. Food & Drug Administration and the European Medicines Agency . The first agency meeting is confirmed and on the calendar with other meetings expected to follow. The meetings will focus on the Company's plans to seek regulatory approval for BiovaxID ® , Biovest's personalized cancer vaccine initially targeting follicular lymphoma, and will help determine the next steps and requirements in ...",
"PowerPoint presentation to be used from time to time in presentations to various third parties" |
|
| 03/15/2011 |
8-K
| Form 8-K - Current report |
| 01/12/2011 |
8-K
| Form 8-K - Current report |
|
|